About the Jefferson Pancreas Tumor Registry (JPTR)
The Jefferson Pancreas Tumor Registry (JPTR) was established to further study the frequency of pancreatic cancer in families with a history of the disease and to identify environmental and occupational risk factors to which patients may have been exposed. Jefferson physicians are also using the results of genetic testing obtained through the Registry to determine the most effective targeted therapies.
Research has shown that certain rare genetic conditions are associated with an increased risk of pancreatic cancer, including familial breast-ovarian cancer, familial melanoma, familial colon cancer, hereditary pancreatitis and Peutz-Jegher's syndrome. While we have not yet identified a causative gene to allow predictive testing for pancreatic cancer, we can offer risk assessments and possibly surveillance with endoscopic ultrasound for patients with a strong family history of pancreatic cancer.
Such high-risk patients may be referred to our gastroenterologists to discuss the pros and cons of invasive surveillance. The goal is to diagnose pancreatic cancer early when it is easier to treat. If the patient does develop pancreatic cancer, Jefferson physicians may use the results of genetic testing to select the most effective therapy. Targeted therapy for pancreas cancer is becoming a reality in part due to recent discoveries made in our laboratory, where molecular studies have clearly indicated survival advantages with the use of targeted chemotherapy treatment.